Contineum Therapeutics, Inc. Class A Common Stock
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications with high unmet need in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idio… Read more
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) - Total Liabilities
Latest total liabilities as of September 2025: $10.38 Million USD
Based on the latest financial reports, Contineum Therapeutics, Inc. Class A Common Stock (CTNM) has total liabilities worth $10.38 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Contineum Therapeutics, Inc. Class A Common Stock - Total Liabilities Trend (2021–2024)
This chart illustrates how Contineum Therapeutics, Inc. Class A Common Stock's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Contineum Therapeutics, Inc. Class A Common Stock Competitors by Total Liabilities
The table below lists competitors of Contineum Therapeutics, Inc. Class A Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Yuanta Securities Korea Co Ltd Preference Shares
KO:003475
|
Korea | ₩16.98 Trillion |
|
Opple Lighting Co Ltd
SHG:603515
|
China | CN¥2.61 Billion |
|
International Personal Finance plc
PINK:IPFPF
|
USA | $724.20 Million |
|
E&R Engineering
TWO:8027
|
Taiwan | NT$1.49 Billion |
|
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317
|
China | CN¥327.17 Million |
|
Liuzhou Liangmianzhen Co Ltd
SHG:600249
|
China | CN¥578.12 Million |
|
Dong Fang Offshore Co., Ltd.
TW:7786
|
Taiwan | NT$6.69 Billion |
|
Real Matters Inc
PINK:RLLMF
|
USA | $15.92 Million |
Liability Composition Analysis (2021–2024)
This chart breaks down Contineum Therapeutics, Inc. Class A Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 29.07 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Contineum Therapeutics, Inc. Class A Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Contineum Therapeutics, Inc. Class A Common Stock (2021–2024)
The table below shows the annual total liabilities of Contineum Therapeutics, Inc. Class A Common Stock from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $14.78 Million | -92.55% |
| 2023-12-31 | $198.32 Million | +1644.87% |
| 2022-12-31 | $11.37 Million | +27.28% |
| 2021-12-31 | $8.93 Million | -- |